Ten-Year Analysis of 174,000 Patients Finds GLP-1 Drugs Reduce Heart and Kidney Failure Risks in Type 1 Diabetics

A Nature Medicine study of 174,000 patients shows GLP-1 drugs reduce heart risks by 15% and kidney failure by 19% in people with type 1 diabetes.

By: AXL Media

Published: Mar 23, 2026, 6:07 AM EDT

Source: Information for this report was sourced from Nature Medicine

Addressing the Long-Term Toll of Type 1 Diabetes

Living with type 1 diabetes is a persistent physiological challenge that extends far beyond simple blood sugar management. Even with modern insulin pumps and continuous glucose monitors, the cumulative damage to the vascular and renal systems remains a primary concern for patients reaching middle age. Historical data suggests that approximately 31% of individuals with this condition eventually suffer a major cardiovascular event, while 7% face end-stage kidney disease. Despite these risks, type 1 patients have traditionally been excluded from the landmark clinical trials for GLP-1 drugs, leaving a significant gap in evidence-based adjunctive therapies.

Mimicking Clinical Trials Through Target Trial Emulation

To bridge this information gap, researchers utilized the Optum Labs Data Warehouse, a massive de-identified database containing the records of over 300 million patients. By identifying 174,678 individuals with type 1 diabetes and employing a "sequential target trial emulation" method, the team was able to apply the rigorous standards of a randomized trial to observational data. This statistical approach allowed for a direct comparison between patients who initiated GLP-1 therapy and those who did not, balancing factors like age and weight to ensure the findings were not skewed by baseline health differences.

Substantial Reductions in Cardiorenal Complications

The results over a five-year follow-up period indicate that GLP-1 drugs provide cardiovascular and kidney protection that mirrors the benefits previously seen in type 2 diabetes. Patients using these medications saw their risk of a major cardiovascular event—such as a heart attack or stroke—drop by 15%. Even more significant was the 19% reduction in the risk of end-stage kidney disease, defined as the point at which a patient requires dialysis or a transplant. Additionally, the study recorded an 18% decrease in heart failure cases and a 28% reduction in major adverse liver events among the treatment group.